Application of monoclonal antibodies for endothelin to hypertensive research

Yoshihiko Saito, Kazuwa Nakao, Masashi Mukoyama, Gotaro Shirakami, Hiroshi Itoh, Takayuki Yamada, Hiroshi Arai, Kiminori Hosoda, Shin Ichi Suga, Michihisa Jougasaki, Yoshihiro Ogawa, Shigeyuki Nakajima, Motohiko Ueda, Hiroo Imura

研究成果: Article査読

69 被引用数 (Scopus)


We developed six kinds of monoclonal antibodies against endothelin (ET)-l recognizing different epitopes with high affinities (5x1010 M-1 to 5x1O11 M-1). Using these monoclonal antibodies, we developed radioimmunoassays for ET-1 with different specificities. Crossreactivities with ET-2 ranged from 80% to 100%, and those with ET-3 ranged from 3% to 60%. Patients with essential hypertension (si=20) showed a significant elevation in the plasma ET-l-LI level compared with age-matched control subjects (n = 12) (30.1 ±1.4 pg/ml versus 18.5±0.9 pg/ml, p<0.01). The plasma ET-l-LI level in hypertensive patients in stages II and 111 (World Health Organization classification) was significantly higher than that in those patients in stage I. There was no significant correlation between the plasma ET-l-LI level and systolic blood pressure (r=0.11), diastolic blood pressure (r=-0.13), or age (r=0.24) in all patients studied who had essential hypertension. In the neutralization experiment, monoclonal antibodies attenuated ET-l-induced contraction of rat aortic rings and the pressor action of ET-1 in pithed rats in vivo. The present study demonstrates the elevated plasma ET-l-LI level in patients with essential hypertension. Monoclonal antibodies developed in this study can become powerful tools to investigate the pathophysiological significance of ET in essential hypertension.

出版ステータスPublished - 1990 6月

ASJC Scopus subject areas

  • 内科学


「Application of monoclonal antibodies for endothelin to hypertensive research」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。